Skip to main content

Advertisement

Mineral Metabolism and Bone Disease

Section edited by Adrian Covic

The Mineral Metabolism and Bone Disease section considers manuscripts describing research related to vascular mineralisation and mineral metabolism in relation to the kidneys. Research describing renal associated-bone diseases are also considered. Case reports should be directed to the dedicated Case Reports section and epidemiological studies should be directed to the dedicated Epidemiology and Health Outcomes section.

  1. phosphate homeostasis is mediated through complex counter regulatory feed-back balance between parathyroid hormone, FGF-23 and 1,25(OH)2D. Both parathyroid hormone and FGF-23 regulate proximal tubular phosphat...

    Authors: Forough Saki, Seyed Reza Kassaee, Azita Salehifar and Gholam Hossein Ranjbar Omrani

    Citation: BMC Nephrology 2020 21:176

    Content type: Research article

    Published on:

  2. Patients with primary hyperoxaluria (PH) often develop kidney stones and chronic kidney disease. Noninvasive urine markers reflective of active kidney injury could be useful to gauge the effectiveness of ongoi...

    Authors: Xiangling Wang, Gauri Bhutani, Lisa E. Vaughan, Felicity T. Enders, Zejfa Haskic, Dawn Milliner and John C. Lieske

    Citation: BMC Nephrology 2020 21:133

    Content type: Research article

    Published on:

  3. Vascular calcification progression has been associated with the loss of trabecular bone in chronic kidney disease (CKD) patients. There are few data evaluating the relationship between cortical bone loss and v...

    Authors: Larissa R. Costa, Aluizio B. Carvalho, Amandha L. Bittencourt, Carlos E. Rochitte and Maria Eugênia F. Canziani

    Citation: BMC Nephrology 2020 21:121

    Content type: Research article

    Published on:

  4. Vascular calcification is a major contributing factor to mortality in end stage renal disease (ESRD). Despite the efficacy of phosphate binders to improve hyperphosphatemia, data on vascular calcification are ...

    Authors: A. Neradova, S. P. Schumacher, I. Hubeek, P. Lux, L. J. Schurgers and M. G. Vervloet

    Citation: BMC Nephrology 2017 18:149

    Content type: Research article

    Published on:

  5. The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from three ri...

    Authors: Takashi Shigematsu, Ryoichi Muraoka, Toshitsugu Sugimoto and Yoshiki Nishizawa

    Citation: BMC Nephrology 2017 18:66

    Content type: Research article

    Published on:

  6. Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that...

    Authors: Matthew A. Roberts, Louis Huang, Darren Lee, Robert MacGinley, Stefanie M. A. Troster, Annette B. Kent, Sukhvinder S. Bansal, Iain C. Macdougall and Lawrence P. McMahon

    Citation: BMC Nephrology 2016 17:177

    Content type: Research article

    Published on:

  7. The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse ...

    Authors: Wei Chen, Michal L. Melamed, Thomas H. Hostetter, Carolyn Bauer, Amanda C. Raff, Anthony L. Almudevar, Amy Lalonde, Susan Messing and Matthew K. Abramowitz

    Citation: BMC Nephrology 2016 17:114

    Content type: Research article

    Published on:

  8. Cardiovascular calcifications can be prevented by vitamin K and are accelerated by vitamin K antagonists. These effects are believed to be mainly mediated by the vitamin K-dependent matrix Gla protein. Another...

    Authors: Nadine Kaesler, Svenja Immendorf, Chun Ouyang, Marjolein Herfs, Nadja Drummen, Peter Carmeliet, Cees Vermeer, Jürgen Floege, Thilo Krüger and Georg Schlieper

    Citation: BMC Nephrology 2016 17:52

    Content type: Research article

    Published on:

  9. Fetuin-A is known as a circulating inhibitor of vascular calcification. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients is stil...

    Authors: Hsin-Hung Lin, Hung-Hsiang Liou, Ming-Shiou Wu and Chiu-Ching Huang

    Citation: BMC Nephrology 2016 17:33

    Content type: Research article

    Published on:

  10. Removal of phosphate by peritoneal dialysis is insufficient to maintain normal serum phosphate levels such that most patients must take phosphate binders with their meals. However, phosphate ‘counting’ is comp...

    Authors: Simon Leung, Brendan McCormick, Jessica Wagner, Mohan Biyani, Susan Lavoie, Rameez Imtiaz and Deborah Zimmerman

    Citation: BMC Nephrology 2015 16:205

    Content type: Research article

    Published on:

  11. Hyperphosphataemia is linked to cardiovascular disease and mortality in chronic kidney disease (CKD). Outcome in CKD is also affected by socioeconomic status. The objective of this study was to assess the asso...

    Authors: Marit D. Solbu, Peter C. Thomson, Sarah Macpherson, Mark D. Findlay, Kathryn K Stevens, Rajan K. Patel, Sandosh Padmanabhan, Alan G Jardine and Patrick B. Mark

    Citation: BMC Nephrology 2015 16:194

    Content type: Research article

    Published on:

  12. Understanding the regulation of mineral homeostasis and function of the skeleton as buffer for Calcium and Phosphate has regained new interest with introduction of the syndrome “Chronic Kidney Disease-Mineral ...

    Authors: Anders Nordholm, Maria L Mace, Eva Gravesen, Klaus Olgaard and Ewa Lewin

    Citation: BMC Nephrology 2015 16:29

    Content type: Research article

    Published on:

  13. Polycystic kidney disease (PKD), a genetic disorder characterized by multiple cysts and renal failure at an early age. In children, kidney disease is often accompanied by disordered mineral metabolism, failure...

    Authors: Kaitlin H Maditz, Brenda J Smith, Matthew Miller, Chris Oldaker and Janet C Tou

    Citation: BMC Nephrology 2015 16:13

    Content type: Research article

    Published on:

  14. Dialysis patients suffer from a high burden of cardiovascular disease (CVD). Partly this is due to progressive deterioration of calcium-phosphate homeostasis. Previous studies suggested that besides FGF-23, lo...

    Authors: Maurits S Buiten, Mihály K de Bie, Annet Bouma-de Krijger, Bastiaan van Dam, Friedo W Dekker, J Wouter Jukema, Ton J Rabelink and Joris I Rotmans

    Citation: BMC Nephrology 2014 15:197

    Content type: Research article

    Published on:

  15. Sclerostin (Scl) has recently emerged as a novel marker of bone remodeling and vascular calcification. However, whether high circulating Scl is also a risk factor for death is not well established. The purpose...

    Authors: Flávia Letícia Carvalho Gonçalves, Rosilene M Elias, Luciene M dos Reis, Fabiana G Graciolli, Fernando Godinho Zampieri, Rodrigo B Oliveira, Vanda Jorgetti and Rosa MA Moysés

    Citation: BMC Nephrology 2014 15:190

    Content type: Research article

    Published on:

  16. Mineral disorders are associated with adverse renal outcomes in chronic kidney disease (CKD) patients. Previous studies have associated hypercalcemia and hypocalcemia with mortality; however, the association b...

    Authors: Lee-Moay Lim, Hung-Tien Kuo, Mei-Chuan Kuo, Yi-Wen Chiu, Jia-Jung Lee, Shang-Jyh Hwang, Jer-Chia Tsai, Chi-Chih Hung and Hung-Chun Chen

    Citation: BMC Nephrology 2014 15:183

    Content type: Research article

    Published on:

  17. Demineralisation and bone density loss during immobilisation are known phenomena. However information concerning the extent of calcium loss during immobilisation remains inconsistent within literature. This ma...

    Authors: Matthias Klingele, Sarah Seiler, Aaron Poppleton, Philip Lepper, Danilo Fliser and Roland Seidel

    Citation: BMC Nephrology 2014 15:163

    Content type: Case report

    Published on:

  18. Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications. However, in order to be active, MGP must be phosphorylated and carboxylated, with this last process being depend...

    Authors: Pierre Delanaye, Jean-Marie Krzesinski, Xavier Warling, Martial Moonen, Nicole Smelten, Laurent Médart, Hans Pottel and Etienne Cavalier

    Citation: BMC Nephrology 2014 15:145

    Content type: Research article

    Published on:

  19. AMG 416 is a novel peptide agonist of the calcium-sensing receptor (CaSR). This report describes the activity of AMG 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approv...

    Authors: Sarah Walter, Amos Baruch, Shawn T Alexander, Julie Janes, Eiketsu Sho, Jin Dong, Qun Yin, Derek Maclean, Dirk B Mendel, Felix Karim and Randolph M Johnson

    Citation: BMC Nephrology 2014 15:81

    Content type: Research article

    Published on:

  20. High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD Treat...

    Authors: Pablo Ureña-Torres, Dominique Prié, Karim Keddad, Peter Preston, Paul Wilde, Hong Wan and J Brian Copley

    Citation: BMC Nephrology 2014 15:71

    Content type: Research article

    Published on:

  21. Experimental models are important to the understanding of the pathophysiology of, as well as the effects of therapy on, certain diseases. In the case of chronic kidney disease-mineral bone disorder, there are ...

    Authors: Guaraciaba O Ferrari, Juliana C Ferreira, Raquel T Cavallari, Katia R Neves, Luciene M dos Reis, Wagner V Dominguez, Elizabeth C Oliveira, Fabiana G Graciolli, Jutta Passlick-Deetjen, Vanda Jorgetti and Rosa MA Moysés

    Citation: BMC Nephrology 2014 15:69

    Content type: Research article

    Published on:

  22. Previous studies have shown that treatment with ergocalciferol in patients with CKD stage 3 + 4 is not effective with less than 33% of patients achieving a 25-OH vitamin D target of >30 ng/ml. The aim of this ...

    Authors: Amay Parikh, Herbert S Chase, Linda Vernocchi and Leonard Stern

    Citation: BMC Nephrology 2014 15:47

    Content type: Research article

    Published on:

  23. High iron load might have a number of toxic effects in the organism. Recently intravenous (iv) iron has been proposed to induce elevation of fibroblast growth factor 23 (FGF23), hypophosphatemia and osteomalac...

    Authors: Eva Gravesen, Jacob Hofman-Bang, Maria L Mace, Ewa Lewin and Klaus Olgaard

    Citation: BMC Nephrology 2013 14:281

    Content type: Research article

    Published on:

  24. Chronic kidney disease–mineral and bone disorder (CKD–MBD) is a common complication in CKD patients, particularly in those with end-stage renal disease that requires dialysis. Lanthanum carbonate (LC) is a pot...

    Authors: Chenglong Zhang, Ji Wen, Zi Li and Junming Fan

    Citation: BMC Nephrology 2013 14:226

    Content type: Research article

    Published on:

  25. Vascular calcification (VC) contributes to high mortality rates in chronic kidney disease (CKD). High serum phosphate and FGF23 levels and impaired phosphaturic response to FGF23 may affect VC. Therefore, thei...

    Authors: Lourdes Craver, Adriana Dusso, Montserrat Martinez-Alonso, Felipe Sarro, José M Valdivielso and Elvira Fernández

    Citation: BMC Nephrology 2013 14:221

    Content type: Research article

    Published on:

  26. Sclerostin is a Wnt pathway antagonist regulating osteoblast activity and bone turnover. Here, we assessed the potential association of sclerostin with the development of coronary artery (CAC) and aortic valve...

    Authors: Vincent M Brandenburg, Rafael Kramann, Ralf Koos, Thilo Krüger, Leon Schurgers, Georg Mühlenbruch, Sinah Hübner, Ulrich Gladziwa, Christiane Drechsler and Markus Ketteler

    Citation: BMC Nephrology 2013 14:219

    Content type: Research article

    Published on:

  27. Vitamin D insufficiency correlates with mortality risk among patients with chronic kidney disease (CKD). The survival benefits of active vitamin D treatment have been assessed in patients with CKD not requirin...

    Authors: Zhenfeng Zheng, Huilan Shi, Junya Jia, Dong Li and Shan Lin

    Citation: BMC Nephrology 2013 14:199

    Content type: Research article

    Published on:

  28. Hyperphosphatemia, serum phosphorus ≥ 4.4 mg/dL, is associated with increased risk for chronic kidney disease and cardiovascular disease. Previous studies have shown a weak association between dietary phosphor...

    Authors: Janet M Wojcicki

    Citation: BMC Nephrology 2013 14:178

    Content type: Research article

    Published on:

  29. Achieving target levels of laboratory parameters of bone and mineral metabolism in chronic kidney disease (CKD) patients is important but also difficult in those living with end-stage kidney disease. This stud...

    Authors: István Kiss, Zoltán Kiss, Csaba Ambrus, András Szabó, János Szegedi, József Balla, Erzsébet Ladányi, Botond Csiky, Ottó Árkossy, Marietta Török, Sándor Túri and Imre Kulcsár

    Citation: BMC Nephrology 2013 14:155

    Content type: Research article

    Published on:

  31. KDIGO (Kidney Disease: Improving Global Outcomes) guidelines recommend that a lateral abdominal radiograph should be performed to assess vascular calcification (VC) in dialysis patients. However, abdominal aor...

    Authors: Daqing Hong, Shukun Wu, Lei Pu, Fang Wang, Junru Wang, Zhengtong Wang, Hui Gao, Yue Zhang, Fei Deng, Guisen Li, Qiang He and Li Wang

    Citation: BMC Nephrology 2013 14:120

    Content type: Research article

    Published on:

  32. Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in dialyzed patients.

    Authors: Hyo Jin Kim, Hyunsuk Kim, Nara Shin, Ki Young Na, Yong Lim Kim, Daejung Kim, Jae Hyun Chang, Young Rim Song, Young-Hwan Hwang, Yon Su Kim, Curie Ahn, Joongyub Lee and Kook-Hwan Oh

    Citation: BMC Nephrology 2013 14:112

    Content type: Research article

    Published on:

  33. Biochemical markers of altered mineral metabolism have been associated with increased mortality in end stage renal disease patients. Several studies have demonstrated non-linear (U-shaped or J-shaped) associat...

    Authors: Jaime L Natoli, Rob Boer, Brian H Nathanson, Ross M Miller, Silvia Chiroli, William G Goodman and Vasily Belozeroff

    Citation: BMC Nephrology 2013 14:88

    Content type: Research article

    Published on:

  34. Fibroblast growth factor 23 (FGF23) is the earliest marker of disturbed mineral metabolism as renal function decreases. Its serum levels are associated with mortality in dialysis patients, persons with chronic...

    Authors: Per-Anton Westerberg, Åsa Tivesten, Magnus K Karlsson, Dan Mellström, Eric Orwoll, Claes Ohlsson, Tobias E Larsson, Torbjörn Linde and Östen Ljunggren

    Citation: BMC Nephrology 2013 14:85

    Content type: Research article

    Published on:

Submit manuscript

Follow

2018 Journal Metrics

Advertisement

BMC Nephrology

ISSN: 1471-2369

Contact us